Skip to content

Inflammation and the Heart

Inflammation and the Heart

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01589770
Enrollment
128
Registered
2012-05-02
Start date
2012-08-31
Completion date
2015-01-31
Last updated
2019-05-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Rheumatoid Arthritis

Keywords

rheumatoid arthritis, inflammation

Brief summary

Studies have shown that people with rheumatoid arthritis (RA) have a higher rate of heart disease than people that do not have RA. we believe this is caused by the inflammation produced by RA.

Detailed description

Aim 1: We want to study people with RA to see if we can detect very early changes in their heart muscle and compare these results to people who do not have RA.

Interventions

OTHERcardiac Magnetic Resonance imaging

Sponsors

Arthritis Foundation
CollaboratorOTHER
Vanderbilt University
Lead SponsorOTHER

Study design

Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
OTHER
Masking
SINGLE (Outcomes Assessor)

Masking description

Individuals specialized in cMRI performed the analyses and were blinded to disease status of participants.

Intervention model description

All participants underwent cardiac MRI(cMRI) using a 1.5 tesla Siemens Magnetom Avanto scanner to compare left ventricular structure and Left atrium size.

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* Written informed consent * Age \>= 18 * RA only: meet American College of Rheumatology(ACR)criteria for Diagnosis of RA * Controls only: no evidence of RA or other inflammatory disease

Exclusion criteria

* Previous or current heart failure or ischemic cardiovascular disease (eg stroke, myocardial infarction, angina, CABG, stent). * Atrial fibrillation. * Known structural or functional cardiac abnormality, including pulmonary htn. * Glomerular filtration rate \< 60 ml/min. * Pregnancy or breastfeeding. * Unable to perform MRI (claustrophobia, unable to fit in magnet,pacemaker,defibrillator or non-MR safe implant). * Hypersensitivity to gadolinium.

Design outcomes

Primary

MeasureTime frameDescription
Left Ventricular Mass Indexed to BSA, g/m^2one scan, cross sectional comparisonLeft Ventricular Mass (LVM) is known to increase in proportion to overall body size and differs by gender. To assess an individual's risk for a cardiovascular event based on LVM,an adjustment for the patient's body size should be done. LVM in grams was divided by body surface area in meters squared, to adjust for body size. Body surface area was calculated by square root (height (cm) X weight (kg)/3600).

Secondary

MeasureTime frameDescription
Left Atrium Size, mmone scan, cross sectional comparisonleft atrium size, measured in millimeters

Countries

United States

Participant flow

Recruitment details

Participants were recruited from the Vanderbilt Rheumatology practice, responses to advertisements, and word of mouth. Exclusion criteria included estimated glomerular filtration rate of \<60 ml/min and inability to undergo cardiac MRI.

Participants by arm

ArmCount
Rheumatoid Arthritis Patients
People who have rheumatoid arthritis
59
Controls
people who do not have RA or other inflammatory disease
56
Total115

Withdrawals & dropouts

PeriodReasonFG000FG001
Overall Studyclaustrophobic when entering cardiac MRI21
Overall StudyEGFR <60ml/min64

Baseline characteristics

CharacteristicRheumatoid Arthritis PatientsTotalControls
Age, Continuous53 years53 years52 years
Race (NIH/OMB)
American Indian or Alaska Native
0 Participants0 Participants0 Participants
Race (NIH/OMB)
Asian
0 Participants0 Participants0 Participants
Race (NIH/OMB)
Black or African American
1 Participants2 Participants1 Participants
Race (NIH/OMB)
More than one race
0 Participants0 Participants0 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
0 Participants0 Participants0 Participants
Race (NIH/OMB)
Unknown or Not Reported
0 Participants0 Participants0 Participants
Race (NIH/OMB)
White
58 Participants113 Participants55 Participants
Region of Enrollment
United States
59 participants115 participants56 participants
Sex: Female, Male
Female
45 Participants89 Participants44 Participants
Sex: Female, Male
Male
14 Participants26 Participants12 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
deaths
Total, all-cause mortality
0 / 670 / 61
other
Total, other adverse events
0 / 670 / 61
serious
Total, serious adverse events
0 / 670 / 61

Outcome results

Primary

Left Ventricular Mass Indexed to BSA, g/m^2

Left Ventricular Mass (LVM) is known to increase in proportion to overall body size and differs by gender. To assess an individual's risk for a cardiovascular event based on LVM,an adjustment for the patient's body size should be done. LVM in grams was divided by body surface area in meters squared, to adjust for body size. Body surface area was calculated by square root (height (cm) X weight (kg)/3600).

Time frame: one scan, cross sectional comparison

ArmMeasureValue (MEDIAN)
Rheumatoid Arthritis PatientsLeft Ventricular Mass Indexed to BSA, g/m^243.8 g/m^2
ControlsLeft Ventricular Mass Indexed to BSA, g/m^242.2 g/m^2
Secondary

Left Atrium Size, mm

left atrium size, measured in millimeters

Time frame: one scan, cross sectional comparison

ArmMeasureValue (MEDIAN)
Rheumatoid Arthritis PatientsLeft Atrium Size, mm29 mm
ControlsLeft Atrium Size, mm29 mm

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026